Ziopharm Oncology Announces Poster Presentations at the 2020 American Society of Clinical Oncology Virtual Meeting
April 30 2020 - 8:00AM
Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that it
will be presenting data from its Controlled IL-12 program, or
Ad-RTS-hIL-12 plus veledimex (Ad+V), both as monotherapy and in
combination with a PD-1 inhibitor (nivolumab) for the treatment of
recurrent glioblastoma at the American Society of Clinical Oncology
(ASCO) Annual Meeting, which will be conducted virtually from May
29-31, 2020.
Poster Discussion |
Title: |
Controlled
IL-12 in Combination with a PD-1 Inhibitor Subjects with Recurrent
Glioblastoma |
Presenter: |
E. Antonio Chiocca, MD, PhD |
Abstract: |
2510 |
Poster #: |
1 |
Session: |
Central Nervous System Tumors |
Date: |
Friday, May 29, 2020 |
|
|
Poster Presentations |
Title: |
Survival of Subjects with Recurrent Glioblastoma Receiving
Intratumoral Administration of Controlled IL-12 with Limited
Exposure to Dexamethasone |
Abstract: |
2564 |
Poster #: |
55 |
Session: |
Central Nervous System Tumors |
Date: |
Friday, May 29, 2020 |
|
|
Title: |
Final results of Controlled IL-12 monotherapy in adults with
grade III or IV gliomas |
Abstract: |
3040 |
Poster #: |
104 |
Session: |
Developmental Therapeutics – Immunotherapy |
Date: |
Friday, May 29, 2020 |
These abstracts will be available on the ASCO
website on May 13, 2020 at 5:00 p.m. ET. All posters, including
poster discussions, will be available on the meeting website
beginning Friday, May 29 at 8:00 am ET. A copy of the
posters/presentations will also be made available on the Scientific
and Medical Publications page of Ziopharm’s website.
About Ziopharm Oncology, Inc.
Ziopharm Oncology is an immuno-oncology company focused on
developing end-to-end cost-effective solutions using its non-viral
Sleeping Beauty platform for T-cell receptor (TCR) and chimeric
antigen receptor (CAR) T-cell therapies and immune-stimulating gene
therapy with Controlled interleukin 12 (IL-12). The Sleeping Beauty
platform genetically modifies T cells with DNA plasmids to express
TCRs to target neoantigens inside and outside hotspots for solid
tumors and CAR to target CD19 for blood cancers using the Company’s
“Rapid Personalized Manufacturing” to produce and release CAR-T as
soon as the day after gene transfer. The Sleeping Beauty platform
is being advanced in collaboration with the National Cancer
Institute, The University of Texas MD Anderson Cancer Center and
Eden BioCell. The Company is also developing its Controlled IL-12
platform, or Ad-RTS-hIL-12 plus veledimex, as monotherapy and in
combination with immune checkpoint inhibitors to treat brain
cancer, including in collaboration with Regeneron
Pharmaceuticals.
Forward-Looking Statements
DisclaimerThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts, and in some cases can be identified
by terms such as "may," "will," "could," "expects," "plans,"
"anticipates," and "believes." These statements include, but are
not limited to, statements regarding the Company's business and
strategic plans, the availability of cash resources, the progress
and timing of the Company's research and development programs,
including the anticipated dates for the initiation, completion and
readouts of its clinical trials and the Company’s expectations
regarding the number of patients in its clinical trials. Although
Ziopharm’s management team believes that the expectations reflected
in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are
subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Ziopharm,
that could cause actual results and developments to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties include among other things, changes in our operating
plans that may impact our cash expenditures, the uncertainties
inherent in research and development, future clinical data and
analysis, including whether any of Ziopharm’s product candidates
will advance further in the preclinical research or clinical trial
process, including receiving clearance from the U.S. Food and Drug
Administration or equivalent foreign regulatory agencies to conduct
clinical trials and whether and when, if at all, they will receive
final approval from the U.S. FDA or equivalent foreign regulatory
agencies and for which indication; the strength and enforceability
of Ziopharm’s intellectual property rights; competition from other
pharmaceutical and biotechnology companies as well as risk factors
discussed or identified in the public filings with the Securities
and Exchange Commission made by Ziopharm, including those risks and
uncertainties listed in Ziopharm’s Annual Report on Form 10-K filed
by Ziopharm with the Securities and Exchange Commission. We are
providing this information as of the date of this press release,
and Ziopharm does not undertake any obligation to update or revise
the information contained in this press release whether as a result
of new information, future events or any other reason.
Ziopharm Oncology Contact:
Chris Taylor VP, Investor Relations and Corporate
CommunicationsZiopharm OncologyT: 617.502.1881E:
ctaylor@ziopharm.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Apr 2024 to May 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From May 2023 to May 2024